More GMP Inspections by EMA due to Increasing Quality Issues
Recommendation
10/11 February 2026
Risk analysis, preventive measures and incident management
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In its annual report 2011, the European Medicines Agency (EMA) reported about the number of inspections performed in that year. According to the report, the number of GMP inspection requests exceeded the forecast (375 vs. 245). The EMA explained that the number of API inspections and many so-called "for cause" inspections are the reasons for the increase. Another reason for that increase is the large number of complex cases due to significant GMP or general quality issues.
It is remarkable that the quality defects reported have risen by 38% compared to the year 2010. The agency has started a project to identify the reasons for such quality defects. In parallel, the EMA has enhanced collaboration on sharing information about inspections with other agencies such as the US FDA. It is intended to involve further partners in this process. Already today, the US FDA has access to EudraGMP.
Source: EMA Annual Report 2011
Related GMP News
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight
19.01.2026GMP Auditor Association Developments September through December 2025
03.12.2025What are GMP Audits and what Qualifications do GMP Auditors need to have?
19.11.2025Root Cause Analysis and CAPA - Why FDA Keeps Calling Them Out
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated